Breast cancer is the most common cancer among reproductive aged women, accounting for 30% of all cancers. In the United States during 2005, more than 210,000 new cases of breast cancer were reported and approximately 11,000 occurred in women younger than 40 years. Among the many concerns experienced by patients with breast cancer, fertility issues can be a particular concern. Identifying this need and offering specialized counseling at the earliest possible point in the patient’s care can potentially preserve options for future pregnancy in the young woman with breast cancer.
Breast Cancer Ovarian Tissue Ovarian Stimulation Fertility Preservation Premature Menopause
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
American Cancer Society. Breast cancer facts and figures: 2005-2006. 2005. www.cancer.org.
Ries LAG et al. Seer cancer statistics review. Bethesda: National Cancer Institute; 2006.Google Scholar
Partridge AH et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83.PubMedCrossRefGoogle Scholar
Thewes B et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol. 2005;23(22):5155–65.PubMedCrossRefGoogle Scholar
Oktay K et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;363(9412):837–40.PubMedCrossRefGoogle Scholar
Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;2010(5):422–34.CrossRefGoogle Scholar
Oktay K et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5.PubMedCrossRefGoogle Scholar
Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol. 2005;23(4):766–73.PubMedCrossRefGoogle Scholar
Lee SJ et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–30.PubMedCrossRefGoogle Scholar
Castelo-Branco C et al. Use of gonadotropin-releasing hormone agonists in patients with hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril. 2007;87(3):702–5.PubMedCrossRefGoogle Scholar
Azim AA et al. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2007;92(6):2197–200.PubMedCrossRefGoogle Scholar
Centers for Disease Control and Prevention. Assisted reproductive technology (art) report. Atlanta: Department of Health and Human Services; 2004.Google Scholar
Nasseri A et al. Elevated day 3 serum follicle stimulating hormone and/or estradiol may predict fetal aneuploidy. Fertil Steril. 1999;71(4):715–8.PubMedCrossRefGoogle Scholar
Madrigrano A, Westphal L, Wapnir I. Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg. 2007;194(4):477–81.PubMedCrossRefGoogle Scholar
Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr. 2005;34:57–9.PubMedCrossRefGoogle Scholar
Oktay K et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.PubMedCrossRefGoogle Scholar
Oktay K et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3 885–90.PubMedCrossRefGoogle Scholar